---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011474"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:45:26.768517+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences Q2 2024: Positive Phase 1a data for PMN310; secures up to $122.7M PIPE

## Summary
- Phase 1a of PMN310 in Alzheimer's showed no SAEs; CSF levels >100x oligomer concentration, half-life ~25 days supporting monthly dosing.
- PIPE financing closed July 2024 with initial $30.3M; up to $122.7M total tied to warrant milestones from healthcare specialist investors.
- Cash and equivalents $1.0M at June 30, 2024 (down from $12.6M at Dec 31, 2023); subsequent PIPE strengthens balance sheet.
- Net loss $2.6M for Q2 2024 vs $2.3M in Q2 2023; R&D expenses $1.6M (up $0.6M YoY) driven by PMN310 clinical costs.
- Company expects to report topline results from all five cohorts in H2 2024 and initiate a Phase 1b trial in 100 AD patients.

## SEC filing metadata
- accession: 0001558370-24-011474
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837024011474/0001558370-24-011474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837024011474/pmn-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011474
- JSON: https://secwatch.observer/filing/0001558370-24-011474.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.